X4 Pharmaceuticals (FRA:48Q0) Cyclically Adjusted FCF per Share: €-218.85 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:48Q0 X4 Pharmaceuticals Inc FRA:48Q0
29 GF Score
Price €4.90
! 4 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals Cyclically Adjusted FCF per Share?

X4 Pharmaceuticals FRA:48Q0 29 Cyclically Adjusted FCF per Share is €-218.85 as of Jun. 2026. GuruFocus rates FRA:48Q0 with a GF Score™ of 29/100. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

X4 Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.143. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-218.85 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-02), X4 Pharmaceuticals's current stock price is €4.902. X4 Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-218.85. X4 Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


X4 Pharmaceuticals  (FRA:48Q0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


X4 Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


X4 Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for X4 Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

X4 Pharmaceuticals Cyclically Adjusted FCF per Share Chart

X4 Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

X4 Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -218.85

FRA:48Q0 vs LXEO, GALT, ENTA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, X4 Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


X4 Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


FRA:48Q0
29GF Score
X4 Pharmaceuticals Inc FRA:48Q0
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

X4 Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, X4 Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.143/333.9520*333.9520
=-0.143

Current CPI (Jun. 2026) = 333.9520.

X4 Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201512 0.000 236.525 0.000
201612 -96.742 241.432 -133.815
201703 -106.419 243.801 -145.770
201706 -183.355 244.955 -249.972
201709 -71.433 246.819 -96.651
201712 -137.873 246.524 -186.769
201803 -125.013 249.554 -167.292
201806 -146.063 251.989 -193.572
201809 -87.413 252.439 -115.639
201812 91.123 251.233 121.125
201903 -182.439 254.202 -239.675
201906 -28.811 256.143 -37.563
201909 -23.911 256.759 -31.100
201912 -15.094 256.974 -19.615
202003 -21.820 258.115 -28.231
202006 -15.246 257.797 -19.750
202009 -18.812 260.280 -24.137
202012 -21.747 260.474 -27.882
202103 -22.991 264.877 -28.987
202106 -18.105 271.696 -22.254
202109 -13.637 274.310 -16.602
202112 -17.468 278.802 -20.923
202203 -16.345 287.504 -18.986
202206 -14.828 296.311 -16.712
202209 -7.032 296.808 -7.912
202212 -4.452 296.797 -5.009
202303 -5.090 301.836 -5.632
202306 -3.517 305.109 -3.849
202309 -2.973 307.789 -3.226
202312 -3.841 306.746 -4.182
202403 -4.645 312.332 -4.967
202406 -5.193 314.175 -5.520
202409 -4.592 315.301 -4.864
202412 -4.664 315.605 -4.935
202503 -2.069 319.799 -2.161
202506 -3.497 322.561 -3.620
202509 -0.548 324.800 -0.563
202512 -0.146 324.054 -0.150
202603 -0.134 330.213 -0.136
202606 -0.143 333.952 -0.143

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-218.85 mean?
X4 Pharmaceuticals (FRA:48Q0) has a Cyclically Adjusted FCF per Share of €-218.85 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on X4 Pharmaceuticals and its competitors.
Is X4 Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
X4 Pharmaceuticals' current Cyclically Adjusted FCF per Share is €-218.85. Overall, X4 Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' Cyclically Adjusted FCF per Share compare to LXEO and GALT?
X4 Pharmaceuticals' Cyclically Adjusted FCF per Share of €-218.85 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on X4 Pharmaceuticals and its competitors. X4 Pharmaceuticals's current Cyclically Adjusted FCF per Share is €-218.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (FRA:48Q0) has a current Cyclically Adjusted FCF per Share of €-218.85. The current Cyclically Adjusted FCF per Share is €-218.85. X4 Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For X4 Pharmaceuticals (FRA:48Q0), the current Cyclically Adjusted FCF per Share is €-218.85 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Other Exchanges XFOR:USA
Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
29GF Score

Get the complete analysis for FRA:48Q0

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.90
Price